U.S. markets closed
  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     
  • Dow 30

    33,800.60
    +297.03 (+0.89%)
     
  • Nasdaq

    13,900.19
    +70.88 (+0.51%)
     
  • Russell 2000

    2,243.47
    +0.88 (+0.04%)
     
  • Crude Oil

    59.34
    -0.26 (-0.44%)
     
  • Gold

    1,744.10
    -14.10 (-0.80%)
     
  • Silver

    25.33
    -0.26 (-1.02%)
     
  • EUR/USD

    1.1905
    -0.0016 (-0.13%)
     
  • 10-Yr Bond

    1.6660
    +0.0340 (+2.08%)
     
  • GBP/USD

    1.3706
    -0.0029 (-0.21%)
     
  • USD/JPY

    109.6500
    +0.3860 (+0.35%)
     
  • BTC-USD

    59,087.54
    +544.32 (+0.93%)
     
  • CMC Crypto 200

    1,235.89
    +8.34 (+0.68%)
     
  • FTSE 100

    6,915.75
    -26.47 (-0.38%)
     
  • Nikkei 225

    29,768.06
    +59.08 (+0.20%)
     

QIAGEN (QGEN) Launches QIAcube Connect MDx Platform Globally

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

QIAGEN N.V. QGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories. The platform will now be available in the United States and Canada, the European Union and other markets globally.

Notably, the QIAcube Connect MDx with diagnostic and research protocols can be used together with QIAGEN’s gold standard QIAamp DSP kits and PAXgene Blood RNA extraction kits. The automated platform is a latest instrument from the QIAcube product line carrying in-vitro diagnostic applications (IVD) that tests samples taken from the human body.

This development will strengthen QIAGEN’s automated instrument segment.

More in the News

The latest QIAcube Connect MDx platform is built on the successful installation of more than 9,800 instruments of the QIAcube instrument portfolio. This clinical expansion enhances QIAGEN’s automated sample portfolio led by the QIAsymphony flagship system.

Significance of the Launch

The new QIAcube Connect MDx enhances safety of lab-process with a complete IVD system, which can also be used to prepare SARS-CoV-2 and other viral samples for diagnostic testing.

QIAcube Connect MDx fully automates protein sample processing, which ensures efficient processes, enhances reproducibility with less human error, and reduces applied time. The latest automated QIAcube connect MDx also enables lab technicians to track their instrument’s status remotely with QIAsphere App.

The fully-automated QIAcube connect MDx platform will help researchers avoid repetitive and costly manual processing by allowing laboratories to automate the first steps of molecular diagnostic workflows through the use of QIAGEN’s spin column technologies for DNA, RNA and protein sample processing.

Recent Developments

In February 2021, QIAGEN extended partnership with INOVIO Pharmaceuticals with a new collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies. The collaboration is focused on the development of a diagnostic test that identifies women who are most likely to benefit from clinical use of VGX-3100.

During the month, QIAGEN launched QIAGEN Digital Insights Partnership program for genomic vendors with five initial partnerships to expand customer access and deliver extended genomic solutions for scientists and clinicians. The first group of five new partnerships involves DNAnexus, GNS Healthcare, Personal Genome Diagnostics, ThermoFisher Scientific and the Wellcome Sanger Institute.

Industry Prospects

Per a report by MarketsandMarkets, the global molecular diagnostics market size is projected to reach $1.54 billion by 2023 from $ 7.71 billion in 2018, at a CAGR of 8.4%. To tap into the potential of this growing market, QIAGEN is developing advanced technologies for sample processing to help customers gain valuable insights into samples.

Price Performance

Shares of the company have gained 21.7% in a year’s time compared with the industry’s growth of 10.6%.

Zacks Rank and Key Picks

Currently, QIAGEN carries a Zacks Rank #3 (Hold).

A few better-ranked socks from the broader medical space are Acorda Therapeutics, Inc. ACOR, Atea Pharmaceuticals, Inc. AVIR and Clearside Biomedical, Inc. CLSD, each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1Rank (Strong Buy) stocks here.

Acorda Therapeutics has a projected long-term earnings growth rate of 23%.

Atea Pharmaceuticals has a projected long-term earnings growth rate of 164%.

Clearside Biomedical has an estimated long-term earnings growth rate of 24%.

Bitcoin, Like the Internet Itself, Could Change Everything

Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.

Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 3 crypto-related stocks now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Acorda Therapeutics, Inc. (ACOR) : Free Stock Analysis Report

QIAGEN N.V. (QGEN) : Free Stock Analysis Report

Atea Pharmaceuticals, Inc. (AVIR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research